327 related articles for article (PubMed ID: 12825855)
1. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Vergote I; Robertson JF; Kleeberg U; Burton G; Osborne CK; Mauriac L; ;
Breast Cancer Res Treat; 2003 May; 79(2):207-11. PubMed ID: 12825855
[TBL] [Abstract][Full Text] [Related]
2. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
Cheung KL; Owers R; Robertson JF
Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
Robertson JF; Howell A; Gorbunova VA; Watanabe T; Pienkowski T; Lichinitser MR
Breast Cancer Res Treat; 2005 Jul; 92(2):169-74. PubMed ID: 15986127
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Bundred N
Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
[TBL] [Abstract][Full Text] [Related]
7. Life following aromatase inhibitors--where now for endocrine sequencing?
Johnston SR; Martin LA; Dowsett M
Breast Cancer Res Treat; 2005; 93 Suppl 1():S19-25. PubMed ID: 16247596
[TBL] [Abstract][Full Text] [Related]
8. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Howell A; Robertson JF; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg UR; Vergote I; Erikstein B; Webster A; Morris C
J Clin Oncol; 2002 Aug; 20(16):3396-403. PubMed ID: 12177099
[TBL] [Abstract][Full Text] [Related]
9. Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Telford C; Jones N; Livings C; Batson S
Clin Breast Cancer; 2016 Jun; 16(3):188-95. PubMed ID: 26971303
[TBL] [Abstract][Full Text] [Related]
10. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
11. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
[TBL] [Abstract][Full Text] [Related]
13. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Dodwell D; Vergote I
Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
[TBL] [Abstract][Full Text] [Related]
14. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
15. A new estrogen receptor antagonist--an overview of available data.
Jones SE
Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S19-21; discussion S33-5. PubMed ID: 12353819
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Mauriac L; Pippen JE; Quaresma Albano J; Gertler SZ; Osborne CK
Eur J Cancer; 2003 Jun; 39(9):1228-33. PubMed ID: 12763210
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Vergote I; Abram P
Ann Oncol; 2006 Feb; 17(2):200-4. PubMed ID: 16251200
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F
Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095
[TBL] [Abstract][Full Text] [Related]
19. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
Franco S; Perez A; Tan-Chiu E; Frankel C; Vogel CL
Breast Cancer Res Treat; 2004 Nov; 88(2):103-8. PubMed ID: 15564793
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
Perey L; Paridaens R; Hawle H; Zaman K; Nolé F; Wildiers H; Fiche M; Dietrich D; Clément P; Köberle D; Goldhirsch A; Thürlimann B
Ann Oncol; 2007 Jan; 18(1):64-69. PubMed ID: 17030543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
